| Previous Close | 120 |
| 1-Year Change | 60.75% |
| 6-Months Change | 17.41% |
| 3-Months Change | 7.46% |
| Moving Avg (50d) | 114.67 |
| Moving Avg (200d) | 102.57 |
| ESG Rating | - |
| Exchange | NASDAQ |
| Market Cap. | 2.09B |
| Beta (3-Years) | 1.13 |
| Revenue Growth (ttm) | -24.06% |
| Net Profit Margin (ttm) | 10.73% |
| Return On Assets (ttm) | 2.14% |
| EPS (ttm) | 0.82 |
| PE Ratio (ttm) | 146.34 |
| Dividend Yield | % |
Ask ChatGPT ?
This might take more than 30s in the first call...
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
| Sector: | Health Care |
| Industry: | Biotechnology |
| Country: | United States |
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenix Inc., the company went public in 1992. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and forming partnerships to develop... Wikipedia